Based in North Brunswick, New Jersey, Ascendia Pharmaceuticals is a specialty contract development and manufacturing (CDMO) company dedicated to delivering sophisticated formulations of existing drug products, and enabling formulations for preclinical- and clinical-stage drug candidates. Ascendia Pharmaceuticals is your ideal partner for: · Early stage IND-enabling formulations for toxicology and pharmacokinetic (PK) studies · Rapid development through Phase I CTM materials for oral and parenteral dosage forms · Fast discovery formulation support · Formulation development and CTM manufacturing for specialty pharmaceuticals Ascendia Pharmaceuticals also provides special development programs: · Formulations for poorly soluble and low bioavailability drugs · First-in-man injectable formulations · Nano-emulsion and nano-particle formulations · Peptide formulations · Sustained release by parenteral or oral routes · Development of 505(b)(2) products · Development of complex generics · High potency and DEA controlled drug substances · Ocular formulation development · Animal health formulations
Looking for a particular Ascendia employee's phone or email?
The Ascendia annual revenue was $126.2 million in 2026.
1 people are employed at Ascendia.
Ascendia is based in North Brunswick, New Jersey.
The NAICS codes for Ascendia are [3254, 32, 54, 325, 32541, 541].
The SIC codes for Ascendia are [283, 28].